Evidence for the efficacy of iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer

Anticancer Research

Volumn 31, Issue 4, 2011, Pages 1417-1420

  Fogelman, David R ^a   Wolff, Robert A ^a   Kopetz, Scott ^a   Javle, Milind ^a   Bradley, Charles ^b   Mok, Isabel ^a   Cabanillas, Fernando ^c   Abbruzzese, James L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BiPar Sciences   (United States)

^c Auxilio Cancer Center   (Puerto Rico)

Author keywords

BRCA; Chemotherapy; Iniparib; Pancreatic cancer

Indexed keywords

BRCA2 PROTEIN; CISPLATIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GEMCITABINE; INIPARIB; INTERFERON;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CASE REPORT; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; FATIGUE; FEMALE; GENE MUTATION; HUMAN; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADENOCARCINOMA; BENZAMIDES; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; TREATMENT OUTCOME;

EID: 79956068235     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Wooster R and Weber BL: Breast and ovarian cancer. N Engl J Med 348: 2339-2347, 2003. (Pubitemid 36638109)
2. Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, Jackson R, Southgate C, Singh R, Falconer A, Dearnaley DP, Ardern-Jones A, Murkin A, Dowe A, Kelly J, Williams S, Oram R, Stevens M, Teare DM, Ponder BA, Gayther SA, Easton DF, Eeles RA; Cancer Research UK/Bristish Prostate Group UK Familial Prostate Cancer Study Collaborators; British Association of Urological Surgeons Section of Oncology. Two percent of men with early onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 72: 1-12, 2003.
3. Teng DH, Bogden R, Mitchell J, Baumgard M, Bell R, Berry S, Davis T, Ha PC, Kehrer R, Jammulapati S, Chen Q, Offit K, Skolnick MH, Tavtigian SV, Jhanwar S, Swedlund B, Wong AK and Kamb A: Nat Genet 13: 241-244, 1996.
4. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, Yeo CJ, Jackson CE, Lynch HT, Hruban RH and Kern SE: Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56: 5360-5364, 1996. (Pubitemid 27011364)
5. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A'Hern R, Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JH, de Bono JS and Kaye SB: Inhibition of poly(ADP-Ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134, 2009.
6. Gudmundsdottir K and Ashworth A: The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25: 5864-5874, 2006. (Pubitemid 44453442)
7. Hoeijmakers J: Genome maintenance mechanisms for preventing cancer. Nature 411: 366-374, 2001.
8. Shen S, Weaver Z, Xu X, Li C, Weinstein M, Chen L, Guan XY, Ried T and Deng CX: A targeted disruption of the murine Brca1 gene causes γ-irradiation hypersensitivity and genetic instability. Oncogene 17: 3115-3124, 1998. (Pubitemid 29020807)
9. Patel KJ, Yu VP, Lee H, Corcoran A, Thistlethwaite FC, Evans MJ, Colledge WH, Friedman LS, Ponder BA and Venkitaraman AR: Involvement of BRCA2 in DNA repair. Molecular Cell 1: 347-357, 1998. (Pubitemid 128378883)
10. van der Heijden MS, Brody JR, Dezentje DA, Gallmeier E, Cunningham SC, Swartz MJ, DeMarzo AM, Offerhaus GJ, Isacoff WH, Hruban RH and Kern SE: In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of tumor. Clin Cancer Res 11: 7508-7515, 2005.
11. Ashworth A: A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 22: 3785-3789, 2008.
12. O'Shaughnessy J, Osborne C, Pippen J, Yoffe M, Patt D, Monaghan G, Rocha C, Ossovskaya V, Sherman B and Bradley C: Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol 27: 18s (suppl; Abstr 3), 2009.
13. Comen EA and Robson M: Poly (ADP-ribose) polymerase inhibitors in triple-negative breast cancer. Cancer J 16(1): 48-52, 2010.
14. Couch FJ, Johnson MR, Rabe KG, Brune K, de Andrade M, Goggins M, Rothenmund H, Gallinger S, Klein A, Petersen GM and Hruban RH: The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 16: 342-346, 2007.
15. Berman DB, Costalas J, Schultz DC, Grana G, Daly M and Godwin AK: A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals. Cancer Res 56: 3409-3414, 1996. (Pubitemid 26251628)
16. Ozcelik H, Schmocker B, Di Nicola N, Shi XH, Langer B, Moore M, Taylor BR, Narod SA, Darlington G, Andrulis IL, Gallinger S and Redston M: Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet 16: 17-18, 1997.
17. Figer A, Irmin L, Geva R, Flex D, Sulkes J, Sulkes A and Friedman E: The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumors in Israel. Br J Cancer 84: 478-481, 2001. (Pubitemid 32215873)